GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Future 3-5Y EPS without NRI Growth Rate

CYCC (Cyclacel Pharmaceuticals) Future 3-5Y EPS without NRI Growth Rate : 63.11 (As of Dec. 11, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate is 63.11.

Competitive Comparison of Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate falls into.


Cyclacel Pharmaceuticals  (NAS:CYCC) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Cyclacel Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
MTEM QRON HALB DRMA ENTO GRTX SXTP BTAX SONN SLRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CYCCP.PFD:USA UXI:Germany
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Website
https://cyclacel.com
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017